7/102 sources · 2 publishersUpdated Oct 8, 21:57 UTC
Citizens lifts Rezolute price target to $15 after FDA feedback
Citizens raised its price target for Rezolute Inc. to $15 from $11 following positive FDA feedback on the company's Phase 3 congenital hyperinsulinism data. The stock was trading at $4.33 at the time of the update. Citizens kept a Market Outperform rating on the shares. The FDA recommendation for a pre‑BLA meeting was cited as a key factor.
Why it matters
Citizens says the higher target reflects a greater probability of FDA approval, which could provide significant upside for investors holding the stock.
Key facts
- 1Citizens raised its price target for Rezolute to $15.00 from $11.00. investing.com
- 2The stock currently trades at $4.33. investing.com
- 3The FDA recommended a pre‑BLA meeting for the company's ersodetug program. investing.com
- 4Citizens reaffirmed its Market Outperform rating on Rezolute. tradingview.com
- 5The $15 price target implies a 246.4% upside from the Oct 5 close. tradingview.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.